These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38352873)

  • 1. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
    Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
    Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis.
    Wang J; Zhang K; Liu T; Song Y; Hua P; Chen S; Li J; Liu Y; Zhao Y
    Front Oncol; 2022; 12():974684. PubMed ID: 36158679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
    Yuan Z; Cui H; Wang S; Liang W; Cao B; Song L; Liu G; Huang J; Chen L; Wei B
    Front Oncol; 2023; 13():1103320. PubMed ID: 36776290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
    Wu D; Yang L; Yan Y; Jiang Z; Liu Y; Dong P; Lv Y; Zhou S; Qiu Y; Yu X
    Cancer Med; 2024 May; 13(9):e7176. PubMed ID: 38716645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
    Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
    Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis.
    Wang H; Liang S; Yu Y; Han Y
    Front Oncol; 2024; 14():1276549. PubMed ID: 38292925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
    Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
    Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
    JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
    Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
    Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.
    Feng Y; Guo K; Jin H; Jiang J; Wang M; Lin S
    Front Immunol; 2023; 14():1269067. PubMed ID: 38250059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Huang D; Sun F; Ke L; Li S
    Int Immunopharmacol; 2024 Jun; 138():112576. PubMed ID: 38941672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis.
    Feng Y; Guo K; Jin H; Jiang J; Wang M; Lin S
    Expert Rev Anticancer Ther; 2024; 24(3-4):169-181. PubMed ID: 38436076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
    Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
    Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.
    Zhong WJ; Lin JA; Wu CY; Wang J; Chen JX; Zheng H; Ye K
    Cancer Med; 2024 Feb; 13(3):e7006. PubMed ID: 38400680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer.
    Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
    Front Immunol; 2022; 13():986359. PubMed ID: 36059550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis.
    Xu H; Li T; Shao G; Wang W; He Z; Xu J; Qian Y; Liu H; Ge H; Wang L; Zhang D; Yang L; Li F; Xu Z
    Front Immunol; 2023; 14():1193614. PubMed ID: 37426646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis.
    Wang H; Liu T; Chen J; Dang J
    Front Oncol; 2022; 12():901494. PubMed ID: 36212419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Immunotherapy Improves Treatment for Early Resectable Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis.
    Dong P; Yan Y; Yang L; Wu D; Wang H; Lv Y; Zhang J; Yu X
    J Oncol; 2022; 2022():2085267. PubMed ID: 36213828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
    Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.